Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.
Drug Discovery
-
31 Jan 2017
-
30 Jan 2017
Biscayne Neurotherapeutics raises $3m for antiepileptic compound
Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.
-
27 Jan 2017
Cellestia Biotech raises CHF8m seed financing
Cellestia Biotech has raised CHF8m in funding from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage.
-
25 Jan 2017
Connect secures $25m financing to advance immune modulators clinical development
Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.
-
25 Jan 2017
Discuva secures Innovate UK grant for new antibiotics development
Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.
-
25 Jan 2017
Cue Biopharma raises $26M in funding
Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.
-
25 Jan 2017
ELC Group partners with PSR Group for advanced drug development
Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.
-
25 Jan 2017
Intrexon to buy clinical-stage gene delivery firm GenVec
Intrexon has agreed to acquire clinical-stage company GenVec which has developed the AdenoVerse gene delivery technology.
-
19 Jan 2017
aTyr Pharma’s Resolaris secures FDA fast track status
The US Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma's Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B).
-
19 Jan 2017
Mallinckrodt to pay $100m to settle US charges on drug pricing
Mallinckrodt has agreed to pay $100m to settle the US Federal Trade Commission (FTC) and state charges that it illegally maintained its monopoly of specialty drug used to treat infants.